Hyperius Biotech and Taiwan Bio Therapeutics Inc. have formed a strategic partnership to advance cell and gene therapy (CGT) innovations. Together, we’re combining Hyperius' expertise in de-risking and accelerating CGT assets with Taiwan Bio's world-class cell therapy manufacturing capabilities. This collaboration strengthens our shared mission: bringing cost-effective, cutting-edge therapies to patients in need. Dolores Baksh, Ph.D., CEO of Hyperius: "The synergy from this partnership will support bringing cost-effective, life-saving therapies to patients faster and more efficiently." Stay tuned – more advancements are on the way! #biotech #celltherapy #genetherapy #CGT #innovation #partnership
Hyperius Biotech
Biotechnology Research
Boston, MA 207 followers
Seamlessly merging strategy, insights, and experience to unlock groundbreaking opportunities in cell & gene therapy.
About us
Hyperius Biotech Inc. is a cell & gene therapy venture development organization that utilizes a distinct model featuring a robust ecosystem of strategic partners. We achieve together. The Hyperius approach begins with enabling market-driven, science-based analysis to identify nascent and cutting-edge assets to seed new companies. We are unique in our holistic approach to establishing and nurturing cell & gene therapies and technologies ready for company formation. Assets are incubated and derisked while their capabilities are accelerated together with Hyperius’ strategic partners, including investors, global contract development and manufacturing organizations, leading medical centers, and more. This thorough support is tailored to facilitate both the commercialization of leading-edge cell & gene therapy products and with a clear exit strategy. Our vision is to catalyze innovation at the intersection of science and technology to create a future where leading-edge treatments redefine the possibilities of medical science.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Boston, MA
- Type
- Privately Held
- Specialties
- cell and gene therapy, biotech, biotechnology, partnerships, collaboration, healthcare, health science, healthcare innovation, health technology, venture development, portfolio company, investment, asset pipeline, portfolio companies, intellectual property, business development, return on investment, commercialization, brand development, cell therapy, and gene therapy
Locations
-
Primary
Get directions
Boston, MA, US
Employees at Hyperius Biotech
Updates
-
Exciting news! We are pleased to announce the appointment of Rodney L Rietze, PhD as Executive Chair of the Hyperius Biotech Board of Directors. Rod brings over two decades of leadership in the cell and gene therapy industry, with a strong track record in the discovery, development and launch of innovative biotech solutions that address unmet medical needs. His deep expertise and strategic vision across academic, biotech and pharma environments have contributed to significant advancements in the evolution of this forth pillar of medicine. As we embark on our mission to drive innovation, growth, and access to these life-changing therapeutics, Rod’s guidance will be instrumental in meeting our goals and shaping Hyperius’ long-term success. We’re thrilled to welcome Rod to our team. #HyperiusBiotech #HBI #CellAndGeneTherapy #BiotechLeadership #WeAchieveTogether
-
Hyperius Biotech is excited to announce our participation in the 2024 Cell & Gene Meeting on the Mesa. Our founders will be in Phoenix and would love to connect! Please set up a partnering meeting on the Mesa attendee portal or email info@hyperiusbiotech.com for more information. #CellandGeneTherapy #CellTherapy #GeneTherapy #CGMesa24 #HyperiusBiotech #HBI #meetingonthemesa #biopharma
-
-
Don't miss this important update from Dolores Baksh, CEO and Founding Partner of Hyperius Biotech!
CEO | Executive Leader | Transforming Technologies & Businesses | Operational Excellence | Commercial Execution
I’m thrilled to announce the official launch of Hyperius Biotech, a cell & gene therapy (CGT) venture development organization. At Hyperius, we unlock the potential of orphaned and standalone CGT assets by integrating cutting-edge technologies and creating synergistic platforms that drive continuous therapeutic innovation. Our approach focuses on strategic investment, de-risking development, and accelerating timelines to ensure impactful returns for stakeholders. Through strong partnerships and collaboration, we aim to reduce the cost of personalized cell therapies and advance breakthroughs in this evolving field of medicine. As we embark on this journey, guided by our belief that "we achieve together," I want to thank everyone who has supported us so far. We look forward to making a significant and lasting impact in the CGT space and achieving great things together! Visit our website at hyperiusbiotech.com and stay tuned for more updates. #HyperiusBiotech #HBI #CellAndGeneTherapy #BiotechInnovation #WeAchieveTogether